GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as …

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer Justin Gover, Mr. Giacobello will be based at the Company’s U.S. headquarters in Carlsbad, California. Related to this appointment, on 6 March 2017 Adam George, GW’s Chief Financial Officer since 2012, became Managing Director – UK, a newly-created executive role with broad leadership responsibilities for UK operations, also reporting to Justin Gover.

“These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company. In anticipation of Epidiolex approval and launch, and with GW now solely listed on Nasdaq, we expect to transition from being a Foreign Private Issuer reporting under

... read more at: https://globenewswire.com/news-release/2017/03/07/932696/0/en/GW-Pharmaceuticals-Announces-the-Appointment-of-Scott-Giacobello-as-Chief-Financial-Officer-and-Adam-George-as-Managing-Director-UK.html

by